On November 2, 2021 Veracyte, Inc. (Nasdaq: VCYT) reported that three abstracts highlighting the company’s immuno-oncology offerings for biopharmaceutical researchers will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 36th Annual Meeting, taking place in Washington, DC and virtually, November 10-14, 2021 (Press release, Veracyte, NOV 2, 2021, View Source [SID1234594200]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"It is exciting to have the opportunity to present new data on our Brightplex assays and be able to provide to clinical researchers innovative solutions designed to help them better understand the mechanism of action for therapeutics," said Corinne Danan, Veracyte’s general manager, Biopharma. "This is especially important in the immuno-oncology field where the micro-environment of the tumor plays a key role in cancer progression and response to therapy."
Veracyte acquired the novel Brightplex technology – which combines information from multiplex immunohistochemistry (IHC) and advanced digital pathology analysis to provide a comprehensive picture of the tumor micro-environment – through its acquisition of HalioDx in August 2021.
The following posters will be presented at the SITC (Free SITC Whitepaper) meeting:
Poster Title: "Assessment of the spatial distribution of B cells subpopulations in the tumor microenvironment and tertiary lymphoid structures by Brightplex, a sequential chromogenic multiplex assay"
Abstract number: 57
Session Date/Time: Nov. 12, 7:00 a.m. – 8:00 p.m. ET (on-site) and Nov. 12, 7:00 a.m. ET (ePoster)
Poster Title: "Assessment of the spatial distribution of CD4+ T cells subpopulations in the tumor microenvironment by Brightplex, a sequential chromogenic multiplex assay"
Abstract number: 41
Session Date/Time: Nov. 12, 7:00 a.m. – 8:00 p.m. ET (on-site) and Nov. 12, 7:00 a.m. ET (ePoster)
Poster Title: "Spatial distribution of infiltrating T lymphocytes with Immunoscore CR T Cells Exhaustion test helps stratification of NSCLC patients treated with PD1/L1 inhibitors in the PIONeeR project"
Abstract number: 460
Session Date/Time: Nov. 13, 7:00 a.m. – 8:00 p.m. ET (on-site) and Nov. 12, 7:00 a.m. ET (ePoster)